Product Description
Protamine sulfate (salmine), a basic protein with a molecular weight of 4,626 +/- 109, is a known antiheparin agent which in the absence of heparin demonstrates an anticoagulant activity. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/6846326/)
Mechanisms of Action: Heparin Binder
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Type 1 Diabetes|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20210044 | P3 |
Completed |
Type 2 Diabetes |
2023-04-17 |
|
| CTR20210529 | P3 |
Completed |
Type 2 Diabetes |
2023-02-16 |
|
| CTR20210530 | P3 |
Completed |
Type 2 Diabetes|Type 1 Diabetes |
2023-01-17 |
|
| CTR20131068 | P3 |
Active, not recruiting |
Type 2 Diabetes |
None |
|
| CTR20131064 | P3 |
Active, not recruiting |
Type 2 Diabetes |
None |
|
| CTR20131067 | P3 |
Active, not recruiting |
Type 2 Diabetes |
None |